EA
NTLA icon

Emerald Acquisition’s Intellia Therapeutics NTLA Stock Holding History

Emerald Acquisition’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$270K Sell
15,871
-45,083
-74% -$873K ﹤0.01% 2623
2016
Q2 		$1.3M Buy
+60,954
New +$1.62M ﹤0.01% 2024

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Emerald Acquisition's NTLA Position: Q3 2016 in Review

Emerald Acquisition reduced its Intellia Therapeutics (NTLA) stake by 74% in Q3 2016, selling an estimated $873K and leaving 15,871 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

Emerald Acquisition first reported a position in NTLA in Q2 2016 and has held it in 2 quarters since. The position peaked at $1.3M in Q2 2016. 65 funds tracked by Wall St. Rank hold NTLA as of Q3 2016.

  • Emerald Acquisition held 15,871 shares of Intellia Therapeutics worth $270K as of Q3 2016.
  • Emerald Acquisition sold 45,083 Intellia Therapeutics shares in Q3 2016, an estimated $873K.
  • Intellia Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2623 holding.
  • Emerald Acquisition first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Intellia Therapeutics position peaked at $1.3M in Q2 2016.
  • 65 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.